Natco Pharma Q3FY26 Results: PAT at ₹1,513 Mn, EBITDA at ₹2,168 Mn
Natco Pharma reported Q3FY26 PAT of ₹1,513 Mn and 9MFY26 PAT of ₹11,495 Mn. Q3FY26 EBITDA was ₹2,168 Mn (30.7% margin). Total revenue stood at ₹7,054 Mn. The company acquired a 35.75% stake in Adcock Ingram Holdings Limited and launched Risdiplam in India. An earnings call is scheduled for February 12, 2026.
The results, strategic acquisition, and product launch are significant developments for the company's growth and market position.
The company reported growth in PAT and revenue, launched a new product, and made a strategic acquisition, all positive indicators.
Natco Pharma Limited announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a Profit After Tax (PAT) of ₹1,513 million for Q3FY26, and ₹11,495 million for the nine months ended FY26. Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) stood at ₹2,168 million with an EBITDA Margin of 30.7% for Q3FY26.
Total revenue for Q3FY26 was ₹7,054 million. This includes Pharma Export Formulations at ₹4,214 million and Domestic Pharma Formulations Revenue at ₹1,198 million. The company also launched Risdiplam for Spinal Muscular Atrophy in the Indian market.
Natco Pharma has acquired a 35.75% stake in Adcock Ingram Holdings Limited, South Africa. For the first half of their financial year ending December 31, 2025, Adcock's revenue was ₹2,464 crore and profit after tax was ₹198 crore. Natco accounted for its share of profit, amounting to ₹29.65 crore, with an associate profit reflection of ₹10.90 crore after a one-time amortization of ₹18.75 crore.
The company also provided an update on its product pipeline, including key Para IV products in the USA such as Carfilzomib, Ibrutinib, and Semaglutide. Investments were made in biotechnology companies like eGenesis (US$8 million for xenotransplantation), Cellogen Therapeutics (US$2 million for CAR-T cell therapies), Eyestem (US$1 million for dry AMD), and Stero Therapeutics (US$1 million for metabolic diseases).
Natco Pharma will hold an earnings call on February 12, 2026, at 4 PM IST to discuss the operational and financial performance. The call will be addressed by Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer, and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.